Sugi Predict

Sugi Predict / Targets / PTK6

PTK6

Protein-tyrosine kinase 6 · Q13882 · PTK6 on Sugi Atlas →

58,298 patent compounds predicted against PTK6, 41,629 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL65771 SCHEMBL65771 0.51 5/20
Sb-203580 Sb-203580 (SCHEMBL95208) 0.75 3/20
Sb-203580 Sb-203580 (SCHEMBL146399) 0.75 3/20
Pd-169316 Pd-169316 (SCHEMBL154958) 0.75 3/20
Sb-203580 Sb-203580 (SCHEMBL220990) 0.75 3/20
SCHEMBL178158 SCHEMBL178158 0.70 3/20
SCHEMBL69095 SCHEMBL69095 0.67 3/20
SCHEMBL67376 SCHEMBL67376 0.64 3/20
SCHEMBL66923 SCHEMBL66923 0.60 3/20
SCHEMBL67192 SCHEMBL67192 0.60 3/20
SCHEMBL68165 SCHEMBL68165 0.59 3/20
SCHEMBL67577 SCHEMBL67577 0.58 3/20
SCHEMBL64719 SCHEMBL64719 0.41 3/20
Dasatinib Anhydrous Dasatinib Anhydrous (SCHEMBL8226) 1.00 2/20
Plx-4720 Plx-4720 (SCHEMBL133733) 1.00 2/20
Sb-202190 Sb-202190 (SCHEMBL158854) 1.00 2/20
Tivozanib Tivozanib (SCHEMBL172883) 1.00 2/20
SCHEMBL201744 SCHEMBL201744 1.00 2/20
SCHEMBL201745 SCHEMBL201745 1.00 2/20
Tae-684 Tae-684 (SCHEMBL282775) 1.00 2/20

Clinical trials — most relevant to PTK6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF PHASE3COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) PHASE2COMPLETED
Protein Tyrosine Kinases (PTK) in Multiple Myeloma PHASE2COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma PHASE1/PHASE2COMPLETED
Ruxolitinib in Estrogen Receptor Positive Breast Cancer PHASE2COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） PHASE2RECRUITING
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP PHASE2COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
The Clinical Application of 68Ga Labeled ssDNA Aptamer Sgc8 in Healthy Volunteers and Colorectal Patients EARLY_PHASE1UNKNOWN
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer nanUNKNOWN
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer nanRECRUITING
The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer nanRECRUITING
Aetiology And Outcome Of Children With Thrombocytosis Admitted to Assiut University Children Hospital nanUNKNOWN
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) nanRECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a PTK6 binder may also engage these)

ProteinNameSimilarity
Q64434 — 0.997 Q64434 →
P42682 — 0.992 P42682 →
P41243 — 0.992 P41243 →
SRMS Tyrosine-protein kinase Srms 0.991 landscape →
Q62270 — 0.991 Q62270 →
P41241 — 0.990 P41241 →
MATK Megakaryocyte-associated tyrosine-protein kinase 0.989 landscape →
Q922K9 — 0.989 Q922K9 →
P32577 — 0.988 P32577 →
P00526 — 0.987 P00526 →
CSK Tyrosine-protein kinase CSK 0.987 landscape →
FRK Tyrosine-protein kinase FRK 0.987 landscape →
Q0VBZ0 — 0.987 Q0VBZ0 →
P41239 — 0.986 P41239 →
BLK Tyrosine-protein kinase Blk 0.986 landscape →
ITK Tyrosine-protein kinase ITK/TSK 0.985 landscape →
P16277 — 0.984 P16277 →
Q62662 — 0.984 Q62662 →
FGR Tyrosine-protein kinase Fgr 0.984 landscape →
TXK Tyrosine-protein kinase TXK 0.983 landscape →
P13116 — 0.983 P13116 →
P00544 — 0.983 P00544 →
P25020 — 0.982 P25020 →
P31693 — 0.982 P31693 →
P63185 — 0.981 P63185 →
P41242 — 0.981 P41242 →
P13115 — 0.981 P13115 →
Q5PXS1 — 0.981 Q5PXS1 →
P42690 — 0.980 P42690 →
Q03526 — 0.979 Q03526 →